East Rutherford, NJ – April 19, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices. Cambrex’s commitment to the environment, health and safety underpins our activities across our sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to our ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com. In connection with today’s announcement, Trillium Asset Management, LLC informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex has appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.
For more information, please visit www.cambrex.com
Tom Vadaketh, Executive VP & CFO
Tel: +201 804 3033